Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of MHS552 in Adult SLE Participants
NCT05203419Phase 1Terminated
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MHS552 in systemic lupus erythematosus (SLE) (6 arms), sponsored by Novartis. Primary endpoints: Adverse Events and Serious Adverse Events. Started Mar 2022; status: terminated.
02
Drugs
MHS552
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05203419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203419.